Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Man triggers smoke bomb during failed crypto robbery - 2The Benefits of Rehearsing Careful Nurturing
- 3South African radio presenter among five charged over Russia recruitment plot
- 4Rights group: At least 2,500 deaths during protest crackdown in Iran
- 5Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- Figure out How to Track and Anticipate Future Cd Rates
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Fossils unearthed in Morocco are first from little-understood period of human evolution
- 5 Arising Professions in Environmentally friendly power
- Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- New science points to 4 distinct types of autism
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
